ICU Medical (NASDAQ:ICUI) Stock Rating Upgraded by Wall Street Zen

ICU Medical (NASDAQ:ICUI) was upgraded by Wall Street Zen from a “buy” rating to a “strong-buy” rating in a report issued on Saturday.

Other equities research analysts also recently issued research reports about the stock. Sanford C. Bernstein downgraded shares of ICU Medical to a “market perform” rating in a research report on Monday, June 15th. Jefferies Financial Group raised shares of ICU Medical to a “strong-buy” rating in a research report on Thursday, May 7th. Zacks Research lowered shares of ICU Medical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Weiss Ratings upgraded ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 23rd. Finally, KeyCorp increased their target price on ICU Medical from $164.00 to $182.00 and gave the stock an “overweight” rating in a report on Tuesday, July 21st. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $192.80.

ICU Medical Stock Performance

NASDAQ:ICUI opened at $184.56 on Friday. The business’s 50-day simple moving average is $151.64 and its 200-day simple moving average is $140.92. ICU Medical has a fifty-two week low of $107.00 and a fifty-two week high of $192.85. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.43 and a quick ratio of 1.21. The stock has a market capitalization of $4.61 billion, a PE ratio of 156.41, a price-to-earnings-growth ratio of 2.58 and a beta of 0.74.

ICU Medical (NASDAQ:ICUI) last announced its earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 EPS for the quarter, topping the consensus estimate of $1.91 by $0.46. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The firm had revenue of $547.88 million for the quarter, compared to the consensus estimate of $533.44 million. During the same period last year, the company posted $2.10 EPS. The business’s quarterly revenue was up .5% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Sell-side analysts expect that ICU Medical will post 6.51 earnings per share for the current fiscal year.

Insider Activity

In related news, VP Virginia Ruth Sanzone sold 2,447 shares of the stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $124.08, for a total transaction of $303,623.76. Following the completion of the transaction, the vice president directly owned 19,460 shares of the company’s stock, valued at approximately $2,414,596.80. This represents a 11.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director David C. Greenberg sold 2,424 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total value of $297,933.84. Following the completion of the transaction, the director owned 7,960 shares of the company’s stock, valued at approximately $978,363.60. This represents a 23.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 2.10% of the company’s stock.

Institutional Investors Weigh In On ICU Medical

Several large investors have recently made changes to their positions in ICUI. BlackRock Inc. bought a new stake in ICU Medical during the second quarter worth $550,250,000. Millennium Management LLC grew its position in shares of ICU Medical by 173.4% in the 3rd quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier’s stock valued at $130,638,000 after acquiring an additional 690,694 shares during the period. Norges Bank bought a new position in shares of ICU Medical in the 4th quarter valued at about $58,083,000. Reinhart Partners LLC. acquired a new position in shares of ICU Medical during the 2nd quarter worth about $46,148,000. Finally, Thrivent Financial for Lutherans increased its stake in shares of ICU Medical by 1,604.0% during the 4th quarter. Thrivent Financial for Lutherans now owns 303,457 shares of the medical instruments supplier’s stock worth $43,294,000 after purchasing an additional 285,648 shares during the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.

Key ICU Medical News

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Quarterly earnings beat expectations: ICU Medical reported second-quarter adjusted EPS of $2.37, up from $2.10 a year earlier and well above the $1.91 analyst consensus. Revenue reached $547.9 million versus expectations of $533.4 million, with infusion systems cited as a key growth driver. ICU Medical Q2 results beat analyst expectations, driven by infusion systems
• Positive Sentiment: Higher 2026 earnings outlook: The company raised or updated fiscal 2026 EPS guidance to $8.60–$9.00, above the approximately $7.83 consensus estimate. This indicates management expects stronger profitability than Wall Street previously modeled. ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance
• Positive Sentiment: Analysts raised price targets: Piper Sandler increased its target from $163 to $195 and maintained an “overweight” rating. Needham raised its target from $165 to $187 and reiterated a “buy” rating. The revisions reinforce the view that the earnings beat and guidance update improve ICU Medical’s growth outlook. ICU Medical Analysts Boost Their Forecasts Following Upbeat Q2 Earnings
• Neutral Sentiment: Valuation remains demanding: Despite the favorable earnings news, ICU Medical trades at a high earnings multiple, meaning further gains may depend on the company delivering against its elevated guidance and sustaining growth.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.